Summit Therapeutics has abruptly pulled a $500 million share sale just one day after announcing it, citing “market conditions” for the cancellation. The move involves the developer of ivonescimab, a leading PD-1/VEGF bispecific antibody for cancer.
The company’s shares have struggled to break out following recent clinical data milestones, suggesting investor caution despite the drug’s promise. The cancellation underscores volatility in biotech financing even for high-profile assets.
Summit had launched the offering through an at-the-market (ATM) program on Wednesday, but reversed course by Thursday. Analysts speculate the rapid reversal may reflect lackluster demand or a strategic pivot to alternative funding.
The drug, ivonescimab, remains a key player in the PD-1/VEGF space, competing with established checkpoint inhibitors. However, the financing hiccup raises questions about the company's near-term cash runway and ability to fund late-stage trials without diluting shareholders.
Some experts caution that the stock's stagnation may signal broader skepticism about the drug's differentiation versus existing therapies, though no new safety or efficacy data prompted the move.